In today’s recent session, 92.98 million shares of the Xilio Therapeutics Inc (NASDAQ:XLO) have been traded, and its beta is -0.26. Most recently the company’s share price was $1.45, and it changed around $0.79 or 120.70% from the last close, which brings the market valuation of the company to $66.34M. XLO at last check was trading at a discount to its 52-week high of $1.93, offering almost -33.1% off that amount. The share price’s 52-week low was $0.50, which indicates that the recent value has risen by an impressive 65.52% since then. We note from Xilio Therapeutics Inc’s average daily trading volume that its 10-day average is 0.15 million shares, with the 3-month average coming to 484.20K.
Xilio Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended XLO as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Xilio Therapeutics Inc is expected to report earnings per share of -0.24 for the current quarter.
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Instantly XLO has been showing a green trend so far today with a performance of 120.70% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.5200 on recent trading dayincreased the stock’s daily price by 4.61%. The company’s shares are currently up 51.83% year-to-date, but still up 109.30% over the last five days. On the other hand, Xilio Therapeutics Inc (NASDAQ:XLO) is 31.82% up in the 30-day period. We can see from the shorts that 0.2 million shares have been sold at a short interest cover period of 0.47 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 79.29% from its current value. Analyst projections state that XLO is forecast to be at a low of $7 and a high of $7.
Xilio Therapeutics Inc (XLO) estimates and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -44.91%. Xilio Therapeutics Inc earnings are expected to increase by 59.04% in 2025, but the outlook is positive 45.49% per year for the next five years.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 39.17% of Xilio Therapeutics Inc shares, and 28.32% of them are in the hands of institutional investors. The stock currently has a share float of 46.55%. Xilio Therapeutics Inc stock is held by 33.0 institutions, with BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC being the largest institutional investor. By 2024-06-30, it held 13.5618% of the shares, which is about 3.79 million shares worth $3.59 million.
ROCK SPRINGS CAPITAL MANAGEMENT LP, with 10.7595% or 3.0 million shares worth $2.85 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024. The former held 739.56 shares worth $0.97 million, making up 1.68% of all outstanding shares. On the other hand, Fidelity Extended Market Index Fund held roughly 181.63 shares worth around $0.24 million, which represents about 0.41% of the total shares outstanding.
